Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Further“
Suchtreffer
Begriffe & Kennungen
Metalyse · 4.3 · Furthermore, Metalyse is contraindicated in the following situations because thrombolytic therapy is associate
Eintrag öffnenNemluvio · 4.8 · In atopic dermatitis, the long-term safety of nemolizumab is being further assessed in an open-label extension
Eintrag öffnenNexavar · 4.8 · 11 Further information on selected adverse drug reactions
Eintrag öffnenNivestim · 4.8 · There is insufficient data to further evaluate filgrastim use in paediatric subjects.
Eintrag öffnenOfev · 4.8 · 11 For further information about special populations, recommended measures and dosing adjustments in case of d
Eintrag öffnenPrezista · 4.5 · Unlike ritonavir, cobicistat does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. For further in
Eintrag öffnenPrezista · 4.5 · Unlike ritonavir, cobicistat does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1. For further in
Eintrag öffnenProQuad · 4.3 · Pregnancy. Furthermore, pregnancy should be avoided for 1 month following vaccination (see section 4.6).
Eintrag öffnenQuinsair · 4.5 · Furthermore, clinical data do not suggest interaction with P-glycoprotein (P-gp) substrates such as digoxin.
Eintrag öffnenRaloxifene Teva · 4.8 · One further change was seen which was not statistically significant (p > 0.05), but which did show a significa
Eintrag öffnenRatiograstim · 4.8 · There is insufficient data to further evaluate filgrastim use in paediatric subjects.
Eintrag öffnenRixathon · 4.8 · 21 Re-treatment The percentage of patients reporting adverse reactions upon re-treatment with further courses
Eintrag öffnenRiximyo · 4.8 · 21 Re-treatment The percentage of patients reporting adverse reactions upon re-treatment with further courses
Eintrag öffnenRybelsus · 4.8 · Table 1 lists adverse reactions identified in phase 3 trials (further described in section 5.1) and post- mark
Eintrag öffnenRybelsus · 4.8 · Table 1 lists adverse reactions identified in phase 3 trials (further described in section 5.1) and post- mark
Eintrag öffnenSapropterin Dipharma · 4.8 · In a further clinical trial, approximately 30% of the 27 children aged below 4 years who received treatment wi
Eintrag öffnenSapropterin Dipharma · 4.8 · In a further clinical trial, approximately 30% of the 27 children aged below 4 years who received treatment wi
Eintrag öffnenSeebri Breezhaler · 4.8 · The safety profile is further characterised by other symptoms related to the anticholinergic effects, includin
Eintrag öffnenSiiltibcy · 4.8 · #: Please refer to “Description of selected adverse reactions” for further details.
Eintrag öffnenSlenyto · 4.8 · Furthermore, in ASD and neurogenetic children treated with 2-6 mg of the adult formulation under a Temporary R
Eintrag öffnen